Objectives: To evaluate the relationship between the mortality rates associated with psychiatric conditions like depression and schizophrenia compared with chronic medical conditions like hypertension and diabetes. Methods: Examined clinical trial safety data from New Drug Approval programmes reviewed by the US Food and Drug Administration and calculated all-cause and suicide/non-suicide mortality rates per 100,000 patient-exposure-years (PEY) for seven diabetes, 12 hypertension, 11 depression, and nine schizophrenia programmes (126,151 patients, 63,106.3 PEY). Results: Depression (894.8 ± 201.2) and schizophrenia (935.3 ± 214.6) had significantly higher all-cause mortality rates than diabetes (462.8 ± 70.8) and hypertension (448.4 ± 123.1). Psychiatric conditions had 1.9-2.1Â the medical conditions' mortality (p < 0.001). Non-suicide mortality rates for depression (506.2 ± 151.3), schizophrenia (550.9 ± 164.7), diabetes (457.2 ± 70.4) and hypertension (430.8 ± 120.6) were comparable. Only antidiabetics showed a signal for all-cause mortality (reduction of 37%, p ¼ 0.008). Conclusions: Depression and schizophrenia trial patients had comparable (if not higher) allcause mortality rates as older populations in diabetes and hypertension trials, even when excluding suicides. While generalizability of the rates themselves is limited, this study can adequately estimate the relational mortality among these conditions because of the high internal consistency of clinical trials. Potential signals for mortality reduction with active treatment should be considered for all investigational medications for chronic conditions with increased mortality, including psychotropics.
Introduction
It is well-established that mortality among patients with schizophrenia (Saha et al. 2007; Chesney et al. 2014 ) and depression (Neeleman 2001; Cuijpers et al. 2014 ) is high. Meta-analyses of population studies have estimated a 60-70% increase in the rate of allcause mortality in persons with depression (Neeleman 2001; Cuijpers et al. 2014) . For those diagnosed with schizophrenia it is even higher, with an approximate 130-158% increase in rate of death by all causes (Saha et al. 2007; Chesney et al. 2014) . However, population studies are difficult to uniformly control, and issues regarding the validity of the diagnostic measure and exclusivity of illness, as well as historical population effects, can strongly influence results.
In addition, it is unclear from these heterogeneous studies how mortality rates in psychiatric illnesses compare to the heightened mortality in chronic medical conditions. In order to investigate this question, we compared the mortality in drug development programmes evaluating investigational medications in patients with depression and schizophrenia and in programmes for two medical conditions: diabetes mellitus type 2 and hypertension.
We considered diabetes and hypertension to be suitable medical illnesses for comparison with depression and schizophrenia because, like depression and schizophrenia, diabetes and hypertension are chronic conditions that require ongoing management. They are also well known as mortal illnesses (DeFelice et al. 2008; Gerstein et al. 2008; Eeg-Olofsson et al. 2010) , carrying a significant risk of death. Finally, all four of these conditions have been extensively studied in the context of clinical trials, providing sufficient data to compare mortality across conditions.
There is some evidence supporting the notion that the mortality risk among patients with psychiatric illnesses may be decreased by psychotropics (Haukka et al. 2008; Shah et al. 2014; Khan et al. 2013; Pompili et al. 2016; Reutfors et al. 2016 ). On the other hand, the evidence is also mixed (Weinmann et al. 2009; Hayes et al. 2015; Wimberley et al. 2017 ) and inconclusive (Takeuchi et al. 2016; Zivin et al. 2016) . For this reason, it is worth examining whether mortality reduction with antidepressants and/or antipsychotics is apparent in clinical trial data. Furthermore, because it is assumed that any increased mortality in psychiatric conditions is predominantly driven by the increased risk of death by suicide, we aimed to evaluate the contribution of suicide and non-suicide mortality in these data For diabetes and hypertension, the primary focus is on cardiovascular (CV) deaths. Mortality reduction as a goal of pharmacological treatment has been a driving factor in the development of drugs for these conditions (MacMahon et al. 1986 ). Pharmacological intervention that provides a controlled reduction of HbA1c level and blood pressure has been shown to reduce mortality rates, particularly deaths from CV causes (Antonakoudis et al. 2007; The Action to Control Cardiovascular Risk in Diabetes Study Group 2008; Papp et al. 2012; Barengo et al. 2013) . Public health agencies worldwide have incorporated pharmacological management of these illnesses into their policies and, as a result, the mortality associated with these illnesses has declined (Paul 1971; Nwachuku and Cutler 1997; Li et al. 2012; Klafke et al. 2015) .
Given the fact that aggressive detection and management of diabetes and hypertension have led to significant decreases in the mortality among patients with these disorders, it is important to explore the possibility that a similar approach may also decrease the mortality associated with psychiatric illnesses. If comparable mortality risk can be established between these four conditions, diabetes, hypertension, depression and schizophrenia, it would provide a starting point and rationale to develop future models to reduce mortality among patients with schizophrenia and depression.
To this end, we decided to access the data contained in the Integrated Safety Summaries presented for approval by the US Food and Drug Administration (FDA) for new investigational medications. These data are comprehensive and typically presented clearly with corresponding exposure. The requirements for participation in clinical trials also provide us with a more selective sample that may address the issues of diagnostic validity and exclusivity of illness that population studies are subject to.
Based on prevailing assumptions in the medical field and the amount of time and resources dedicated to addressing the mortality of the two medical conditions, diabetes and hypertension, we hypothesised that these two conditions would have higher all-cause mortality rates than the two psychiatric conditions, depression and schizophrenia. In addition, we hypothesised that mortality would appear to be lower with investigational drugs than with placebo; however, that these comparisons would be limited by statistical power. Lastly, we hypothesised that the majority of the heightened mortality risk in the two psychiatric conditions would be driven by suicide deaths and that excluding deaths from suicide would enhance the difference in mortality rates between medical and psychiatric conditions even further.
Methods

FDA database
We used the US FDA database (https://www.accessdata.fda.gov/scripts/cder/daf/) because it contains standardised and verified reports of safety data from clinical trials conducted for the approval of new investigational medications. Medical reviewers for New Drug Approval (NDA) programmes assess the quality of safety data presented in the Integrated Safety Summary (ISS) section of the approval packet.
ISS reports are required to list all fatal events (and causes) that occurred within the safety observation period (typically the time after clinical trial randomisation until 30 days after treatment conclusion) regardless of the possibility that the fatality was related to treatment. The data reviewed at the time of the initial submission of the NDA is referred to as the original safety population dataset (or the NDA dataset). Some programmes have published safety updates in addenda to the original dataset, and we included these updates if the data was entirely novel to the original NDA.
Inclusion/exclusion criteria for programmes
We included the safety reviews from all NDAs that we could access on the FDA website for new investigational antihyperglycemics, antihypertensives, antidepressants and antipsychotics. We also included programmes for new molecular formulations (such as extended-release formulations) and combinations of these medications if the data used for safety evaluation were not already presented in the approval programme for a prior application. Included programmes had to provide sufficient mortality data and corresponding exposure for both drug and placebo treatment.
Programmes and sections of the safety dataset were excluded in cases where the data were still blinded, patient exposure years (PEY) were not given individually for drug or placebo, and when estimates for PEY were not given or able to be accurately calculated based on reported data. When pertinent information about the deaths was not able to be identified (i.e., corresponding PEY or treatment condition) or when the numbers reported in various tables and text did not substantiate one another, these data were not included. In addition, programmes were excluded if they used data from trials that enrolled patients with indications other than the four conditions of interest for this analysis.
Diabetes programmes
Reported safety data came from monotherapy and adjunctive clinical trials of antihyperglycemic agents in adult patients with diabetes mellitus type 2 and insufficient glycemic control typically defined as an HbA1c level of approximately 7-10% inclusive.
There were originally 22 antihyperglycemic programmes for inclusion in the analysis of diabetes. Seven programmes, pioglitazone (1999), glyburide/ metformin (2000), metformin (MR 2000 , XT 2004 , XR 2005 , bromocriptine (2009) and alogliptin (2013) did not report PEY data for drug and/or placebo and therefore were excluded. Five programmes, sitagliptin/ metformin (2007), saxagliptin/metformin (2010), linagliptin/metformin (2012), sitagliptin/metforminXR (2012) and alogliptin/metformin (2013) included data that had been presented in prior NDA applications and therefore did not contain entirely unique data. Three programmes, saxagliptin (2009), alogliptin/ pioglitazone (2013) and dapagliflozin (2014) reported PEY and deaths for all controls rather than giving placebo data exclusively. Exclusion of these 15 programmes left seven programmes for analysis.
Hypertension programmes
The reported safety data came from monotherapy, adjunctive and open-label clinical trials evaluating antihypertensive agents in adult patients with essential hypertension, typically diagnosed as diastolic blood pressure exceeding 90 mmHg.
There were 23 antihypertensive programmes for consideration. Four programmes, isradipine (1990), valsartan (1996) , telmisartan (1998) and olmesartan (2002) did not give PEY data for drug and/or placebo treatment groups. Seven programmes, valsartan/HCT (1998), candesartan/HCT (2000), telmisartan/HCT (2000), eprosartan/HCT (2001), olmesartan/HCT (2003), aliskiren/HCT (2008) and aliskiren/amlodipine (2010) included data from trials conducted in the NDA programmes for prior submissions. Exclusion of these 11 programmes yielded 12 antihypertensive programmes.
Depression programmes
Safety data came from placebo-controlled and openlabel trials of antidepressants for the treatment of adults with major depressive disorder (MDD) as diagnosed by DSM-III or DSM-IV criteria. Mirtazapine (1996) was excluded a priori because tri-and tetracyclic antidepressants may have a different mortality profile than other antidepressants (Khan et al. 2013; Wu et al. 2017 ).
There were 15 antidepressant programmes after the initial collection. Four programmes, fluoxetine (1987), bupropion (1996) , duloxetine (2002) and levomilnacipran (2013) did not report PEY for drug and/or placebo treatment groups. Therefore, there were 11 antidepressant approval programmes included.
Schizophrenia programmes
Safety data came from programmes evaluating the safety of investigational antipsychotics in adult patients with a primary diagnosis of schizophrenia (using DSM-III or DSM-IV criteria) in both open label and placebo-controlled trials.
There were originally 18 antipsychotic programmes for consideration. Five programmes, olanzapine IM-ER (2009), lurasidone (2010), aripiprazole IM (2013), brexipiprazole (2015) and aripiprazole IM (2015) did not give PEY data for the drug and/or placebo treatment groups. Four programmes, olanzapine (1996), quetiapine (1997), ziprasidone (2001) and aripiprazole (2002) included trials evaluating antipsychotic safety in elderly dementia and Alzheimer's patients. Because we could not isolate data from the trials evaluating only patients with schizophrenia, we could not include these four programmes in this analysis. Exclusion of these nine programmes in total left nine remaining programmes for this current analysis.
Patient comorbidities
Patients in trials for all four conditions were required to have other comorbid physical ailments under control through medication ('medically stable'). Diabetes and hypertension patients were not assessed for psychiatric comorbidities while depression and schizophrenia patients were required to be free of diagnosis of other Axis I disorders.
Definition of terms
Patient exposure years (PEY): sum of the duration of exposure to the assigned treatment condition from each patient in the safety population. PEY were taken as reported in the safety summaries and verified as corresponding to the safety population from which the number of deaths were also taken. In cases where total PEY treatment exposure was not already calculated, we calculated PEY by taking the given mean duration of exposure and multiplying by the number of patients.
Mortality rate (per 100,000 PEY): to calculate mortality rate per 100,000 PEY we divided the number of deaths by the corresponding PEY and then multiplied the outcome by 100,000. Unless otherwise noted, the mortality rates referred to in this analysis are inclusive of both drug and placebo treatment conditions.
Statistical measures
Mid-P exact (two-tailed) for the conditional maximum likelihood estimate was used to calculate and determine the significance of rate ratios and confidence intervals for pooled mortality rates were calculated using Fisher's exact statistics. Table 1 summarises the essential data and characteristics of the seven diabetes, 12 hypertension, 11 depression and nine schizophrenia programmes included in this analysis.
Results
Summary of included programmes
All-cause mortality rates for all patients across conditions
In Figure 1 , the confidence intervals for the two psychiatric conditions, depression and schizophrenia, do not overlap with those from the two medical (1999) Figure 1 . All-cause mortality rate per 100,000 PEY for diabetes, hypertension, depression and schizophrenia programmes. The confidence intervals for the two medical conditions (diabetes and hypertension) do not overlap with those for the two psychiatric conditions (depression and schizophrenia) as indicated by the vertical line. The two psychiatric conditions had significantly higher all-cause mortality rates than the two medical conditions. conditions, diabetes and hypertension. The all-cause mortality rates seen in depression (894.8 ± 201.2) and schizophrenia (953.3 ± 214.6) were significantly higher than the all-cause mortality rates seen in diabetes (468.5 ± 68.6) and hypertension (448.4 ± 123.1). Depression had 1.91 (1.45-2.50, p < 0.001) times the mortality compared to diabetes and 2.00 (1.40-2.86, p < 0.001) times the mortality compared to hypertension. Schizophrenia had 2.00 (1.51-2.62, p < 0.001) times the mortality compared to diabetes and 2.09 (1.46-3.00, p < 0.001) times the mortality compared to hypertension.
Drug/placebo differences in all-cause mortality rate Figure 2 plots the all-cause mortality rates for drug and placebo treatment groups in each of the four conditions. Except for diabetes, there is substantial overlap between confidence intervals from drug and placebo for hypertension, depression and schizophrenia. The all-cause mortality reduction seen with antidiabetics was 0.63 (0.45-0.89, p ¼ 0.009), and diabetes was the only condition in which the drug-placebo difference in all-cause mortality reached statistical significance. For hypertension (RR: 0.59, CI: 0.29-1.28, p ¼ 0.163), depression (RR: 1.41, CI: 0.73-3.00, p ¼ 0.338), schizophrenia (RR: 0.92, CI: 0.33-3.69, p ¼ 0.827) the differences between drug and placebo were not statistically significant.
Analysis of the role of suicide in mortality across conditions
Suicides represented a larger portion of the total deaths in depression (33/76: 43.4%) and schizophrenia (30/73: 41.1%) programmes than in programmes for diabetes (2/164: 1.2%) or hypertension (2/51: 3.9%). The suicide rate per 100,000 PEY observed in the ISS reports were 5.6 (±7.8), 17.6 (±24.4), 388.5 (±132.6), 384.4 (±137.5) for diabetes, hypertension, depression and schizophrenia respectively.
Analysis of non-suicide mortality across conditions
When excluding deaths from suicide (Figure 3) , mortality rates were comparable between all four conditions (diabetes, 457.2 ± 70.4; hypertension, 430.8 ± 120.6; depression, 506.2 ± 151.3; schizophrenia, 550.9 ± 164.7) .
Discussion
This study aimed to establish comparative mortality rates for patients participating in clinical trials for psychiatric conditions, depression and schizophrenia, and medical conditions, diabetes and hypertension. In addition, we attempted to evaluate the contribution of suicide in these mortality data and to determine if signal detection for mortality reduction could be found in any of the conditions. Figure 2 . Comparison of all-cause mortality rates between drug and placebo treatment groups for diabetes, hypertension, depression and schizophrenia New Drug Approval programmes. (a) There is substantial overlap in the confidence intervals for hypertension, depression and schizophrenia, while diabetes was found to constitute a significant difference between the estimates of mortality for drug exposure versus placebo exposure. (b) Only the informative part of the confidence interval is shown. The confidence interval would extend to 2159.0 if shown in its entirety.
Contrary to our hypothesis, patients in clinical trials for psychiatric conditions, depression and schizophrenia, had approximately double the all-cause mortality of patients in trials for medical conditions, hypertension and diabetes (Figure 1 ). While these data are surprising, we recognise that patients in clinical trials are not representative of the population of patients with these conditions. Clinical trial participants are likely to represent the healthiest portion of the population as they are highly selected for low comorbidity and they are considered to be 'medically stable'. While this limits the generalizability of these data, the fact that this selection bias occurred in clinical trials for all of the conditions we examined allowed for the cross-condition examination of mortality that we aimed to conduct in this study.
Therefore, these data suggest that the 'healthiest' of the population of depression and schizophrenic patients still died at higher rates than the 'healthiest' of the population of diabetes and hypertension patients in clinical trials. This is even more striking if one considers that suicidality, which is known to be associated with psychiatric illnesses, is systematically screened out of clinical trials such that potential patients who appear to be at higher risk of suicidal behaviour during the trial are excluded from participation (Khan et al. 2018) .
Considering this, the role of suicide in these mortality data is also somewhat surprising. As predicted, the impact of suicide on the mortality of patients in clinical trials for depression and schizophrenia was considerable: suicide accounted for around 40% of the deaths in the psychiatric conditions. On the other hand, suicide was very infrequent in trials for hypertension and diabetes (<4% of deaths). However contrary to our hypothesis, it was found that all four conditions had comparable non-suicide mortality rates (Figure 3) . While death by suicide is a large component of the increased mortality in depression and schizophrenia, non-suicide deaths from causes like CV events and cancers in psychiatric patients are surprisingly quite comparable to those in diabetic or hypertensive patients. This demonstrates the necessity to pay careful attention to the medical needs of psychiatric patients, which may be overlooked too frequently in psychiatric care management.
Finally, signal detection for mortality reduction was only apparent in diabetes trials. As hypothesised, there was a numerically lower all-cause mortality rate with the investigational medication compared to placebo in all conditions except for depression ( Figure 2) . However, the only statistically significant difference in mortality rates between drug and placebo was for diabetes, where it appears that antidiabetics reduced the mortality rates by 37% compared to patients treated with placebo. Due to the small number of observed mortality events and very low patient exposure for placebo in the other conditions, particularly in schizophrenia (PEY ¼ 295.9, Table 1), the mortality rate estimates for placebo were considered highly statistically unstable (resulting in large confidence intervals). It is apparent that the majority of these trials are not intended to pick up a mortality signal, as reliable signal detection with such low placebo exposure is not possible. Therefore, numerical differences in mortality rates between treatment conditions in hypertension, depression and schizophrenia should be viewed cautiously as they may or may not represent true effects. The confidence intervals for these three conditions included values both above and below 1, and therefore not even the direction of active treatment effect (whether it appears to increase or reduce mortality) can be accurately gleaned from these data.
As it stands currently, the effects of pharmacological treatment on mortality are unclear. Low exposure continues to yield statistically unreliable data. Yet, these data show that there is a need for pharmacological intervention to address the mortality (from both suicide and natural causes) associated with depression and schizophrenia. Further development and testing of psychiatric drugs with a specific focus on mortality reduction need to be implemented. Figure 3 . Non-suicide mortality rate for diabetes, hypertension, depression and schizophrenia drug approval programmes. All confidence intervals within the conditions overlap, indicating that there is no significant difference between the non-suicide mortality rates of the four conditions. Such a programmatic approach to mortality reduction was modelled recently by the diabetes drug empagliflozin, which received an indication for CVrelated mortality reduction in 2016. The safety programme in the original NDA(2014) for this drug was the largest that we examined (over 10,000 patients exposed, 2,700 assigned to placebo) and the ISS report showed a nearly 50% reduction in mortality in the drug group as compared to placebo. After conducting an additional supplementary trial (EMPAG-REG OUTCOME) with over 7,000 patients followed for over 3 years, signal detection for CV mortality reduction was achieved and the indication was granted (Boehringer 2014) .
In psychiatry, previous assessments of the treatment effects of clozapine on suicidality (InterSePT Study) (Meltzer et al. 2003 ) have shown associated reductions in suicidal behaviours, including death by suicide. Including surrogate markers as this study did (by evaluating changes in the severity of a patient's score on suicidality tracking measures in addition to recording events) may be useful for meeting statistical requirements.
It is important to note that, because these data do not have strong external validity, they are not intended to serve as estimates of the mortality rates that occur in the general population of patients with these conditions. Instead, this study takes advantage of the internal consistency of these data and contributes to the body of literature on the mortality associated with psychiatric and medical conditions by offering a description of the comparative relationship between mortality rates across conditions. Such internal consistency can be inferred from the strictly enforced rules and expectations regarding trial design, patient selection and safety data recording and analysis involved in the FDA review process for regulatory trials such as these. As far as we are aware, this is the first study evaluating clinical trial mortality data across conditions with the capacity to make apples-to-apples comparisons due to the consistency of methods for measurement, diagnosis and selection of samples between trials and even between conditions. This study has some major limitations. Of primary importance is the fact that these are summary data and therefore individual trial and patient qualities cannot be quantified. Therefore patient comorbidities, severity of illness, concomitant meds and other variables of interest must be generally assumed for the population from the basic inclusion and exclusion criteria inherent in all FDA regulatory trials. Because this study is a first attempt and there are no supporting studies, the results should be viewed with caution.
Population studies may answer some of the questions we have about mortality in the general population, but these data from clinical trials provide the opportunity to compare mortality across conditions in the context of high internal validity and consistency. What these data show is that depression and schizophrenia are highly mortal illnesses. We have in addition shown that, despite representing a younger population, the mortality rates for patients in depression and schizophrenia trials are comparable to those for much older patients in trials of hypertension and diabetes, even when excluding suicides. These data suggest that the model for psychiatric drug development and evaluation should include attention to suicide and non-suicide mortality. Clinical trials have the potential to be an instrumental part of testing the impact of new investigational agents, including psychotropics, on the mortality associated with these conditions.
